First approved in 2020, first-in-class microtubule inhibitor Klisyri (tirbanibulin 1%) reached the market in early 2021, joining a short list of therapies in the US that are available for AK ...

The Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug ...

ADRX-0134 is a preclinical NaPi2b ADC incorporating AP052, the same clinically validated microtubule inhibitor payload used in Adcentrx's lead program, ADRX-0706 (Nectin-4 ADC), currently ...

a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer ...

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report) saw a significant drop in short interest in March. As of March ...

Tau hyperphosphorylation contributes to microtubule destabilization and ... targeting of aberrant tau phosphorylation with kinase inhibitors may be feasible. At present no inhibitors are available ...

with registration-intent topline data anticipated by year end 2026 Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug conjugates (ADCs ...